LXRX Lexicon Corp: Rasio rega marang prakiraan pendapatan
The implementation of AI in molecule discovery is accelerating drug development for Lexicon Pharmaceuticals (LXRX). The forward P/S indicator on this GURU.Markets platform chart confirms this trend, with the metric currently standing at 21.10. High confidence among medical professionals is based on the efficacy of the company's drugs. Business protection relies on patents, although ultimate success depends on FDA verdicts regarding insurance reimbursements.
Ringkesan rincian data analitis Lexicon Corp (LXRX)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Lexicon Pharmaceuticals|LXRX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lexicon Pharmaceuticals|LXRX - Utang perusahaan|Utang-utang marang kapitalisasi buku Lexicon Corp|LXRX - Utang jangka dawa|Kewajiban jangka cendhak perusahaan Lexicon Pharmaceuticals|Rasio cepet lexpharma.com
- rincian asil keuangan lan kelipatan valuasi:
LXRX - Asil keuangan resik|Proyeksi bathi mangsa ngarep Lexicon Pharmaceuticals|LXRX - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep Lexicon Pharma|LXRX - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lexicon Corp|LXRX - Bathi operasional sadurunge amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Lexicon Pharmaceuticals|LXRX - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan lexpharma.com|LXRX - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lexicon Pharmaceuticals
- indikator volume dodolan lan pendapatan:
Ringkesan analitik perusahaan:Lexicon Pharmaceuticals, Inc. LXRX
Lexicon Pharmaceuticals' development of drugs for metabolic diseases is independent of economic cycles; therefore, the business value is determined solely by commercialization success and clinical data. This metric correlates current market capitalization with expected revenue, allowing the forward price-to-sales multiple chart to assess whether the company's shares are overbought relative to projected sales growth rates.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rasio rega marang prakiraan pendapatan Amicus Therapeutics FOLD|89bio.com - Rasio rega marang prakiraan pendapatan|Agios Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Structure Therapeutics Inc|MDXG (MiMedx Group) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan RZLT|MBX (MBX Biosciences Inc) - Multiplikator Forward P/S|altimmune.com (ALT) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S AARD|Multiplikator forward rega marang pendapatan Sagimet Biosciences, Inc. SGMT|Rasio rega marang prakiraan pendapatan BioAge Labs Inc. BIOA|Biomea Fusion Corp (BMEA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|QNCX - Rasio rega marang prakiraan pendapatan|GUTS (fractyl.com) - Kapitalisasi marang prakiraan pendapatan|VTVT (vtvtherapeutics.com) - Multiplikator forward rega marang pendapatan|Agape ATP - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Pluristem Therapeutics|Synlogic Corp - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S LPCN|MTNB (matinasbiopharma.com) - Rega forward marang dodolan|Multiplikator Forward P/S SPRB (Spruce Biosciences, Inc.)|Multiplikator Forward P/S Galecto Inc GLTO|CTCX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan LUMO (Lumos Therapeutics)|Organovo Holdings, Inc. (ONVO) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan radiuspharm.com
